Abstract
During the last few years several immunotherapies have been shown to induce clinical response and/or improve the clinical outcome in a significant number of cancer patients. However, the lack of a human-centered translational approach has led to the accumulation of a multitude of disjointed clinical and basic researches with a consequent disharmonic growth of the scientific knowledge. The huge number of non-evidence-based conjectural hypotheses has competitively interacted with the few evidence-based hypotheses generated by studies conducted in humans leading to the accumulation of several clinical breakdowns and few "mysterious" successes.In the last decade, the availability of high-throughput gene expression profiling has led to the development of novel discovery-driven approaches capable of investigating the tumor/host integration in its globality. Here, we describe in detail gene expression profiling studies that have led to the formulation of a new generation of evidence-based hypotheses explaining the structural basis of the immune-mediated tumor rejection following immunotherapy.
Original language | English |
---|---|
Title of host publication | Cancer Immunotherapy |
Subtitle of host publication | Immune Suppression and Tumor Growth: Second Edition |
Publisher | Elsevier Inc. |
Pages | 373-394 |
Number of pages | 22 |
ISBN (Print) | 9780123942968 |
DOIs | |
State | Published - Jul 2013 |
Keywords
- Adoptive therapy
- Bedside to bench and back
- Biomarker
- CCR5
- CXCR3
- Chemokine
- Gene expression profiling
- Gene signature
- High-throughput technology
- Immunologic constant of rejection
- Immunotherapy
- Interferon signaling
- Interleukin-2
- Microarray
- Vaccine therapy